Company Analysis Henan Lingrui Pharmaceutical Co., Ltd.
1. Summary
Advantages
- The stock's return over the last year (22.67%) is higher than the sector average (-21.98%).
- The company's current efficiency (ROE=21.27%) is higher than the sector average (ROE=6.65%)
Disadvantages
- Price (19.81 Β₯) is higher than fair price (13.2 Β₯)
- Dividends (0%) are below the sector average (0.3991%).
- Current debt level 1.86% has increased over 5 years from 0%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
Henan Lingrui Pharmaceutical Co., Ltd. | Healthcare | Index | |
---|---|---|---|
7 days | -2.8% | -4% | -1.9% |
90 days | -13.1% | -8.6% | -9.5% |
1 year | 22.7% | -22% | 18.8% |
600285 vs Sector: Henan Lingrui Pharmaceutical Co., Ltd. has outperformed the "Healthcare" sector by 44.65% over the past year.
600285 vs Market: Henan Lingrui Pharmaceutical Co., Ltd. has outperformed the market by 3.82% over the past year.
Stable price: 600285 is not significantly more volatile than the rest of the market on "Shanghai Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 600285 with weekly volatility of 0.4359% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (19.81 Β₯) is higher than the fair price (13.2 Β₯).
Price is higher than fair: The current price (19.81 Β₯) is 33.4% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (16.69) is lower than that of the sector as a whole (41.44).
P/E vs Market: The company's P/E (16.69) is lower than that of the market as a whole (64.64).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (3.39) is lower than that of the sector as a whole (3.68).
P/BV vs Market: The company's P/BV (3.39) is higher than that of the market as a whole (3.08).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.86) is lower than that of the sector as a whole (20.2).
P/S vs Market: The company's P/S indicator (2.86) is lower than that of the market as a whole (6.41).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (14.5) is lower than that of the sector as a whole (16.62).
EV/Ebitda vs Market: The company's EV/Ebitda (14.5) is lower than that of the market as a whole (17.31).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 14.91% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (14.91%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0%).
5.4. ROE
ROE vs Sector: The company's ROE (21.27%) is higher than that of the sector as a whole (6.65%).
ROE vs Market: The company's ROE (21.27%) is higher than that of the market as a whole (8.24%).
5.5. ROA
ROA vs Sector: The company's ROA (12.46%) is higher than that of the sector as a whole (3.59%).
ROA vs Market: The company's ROA (12.46%) is higher than that of the market as a whole (4.08%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (0%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.3991%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0% has been steadily paid over the past 7 years, DSI=0.86.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 4 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (60.6%) are at a comfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription